Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PLAA | Q9Y263 | 5/20 | 0.49 |
| ▸ | DBH | P09172 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309743 | 1.00 | KDM4E (0.53) | KDM4EUSP2ALDH1A1CA12CA1 | |
| SCHEMBL22763940 | 0.87 | CA12 (0.46) | KDM4EUSP2ALDH1A1CA12CA1 | |
| SCHEMBL10042364 | 0.85 | ALDH1A1 (0.50) | KDM4EUSP2ALDH1A1CA12CA1 | |
| SCHEMBL6662611 | 0.85 | CA12 (0.47) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL21462661 | 0.84 | CA12 (0.50) | KDM4EUSP2ALDH1A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL11269811 | 0.82 | LCK (0.51) | KDM4EUSP2ALDH1A1POLBPLAA | |
| SCHEMBL9768140 | 0.80 | ALPG (0.43) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL10538218 | 0.79 | EGFR (0.48) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL26491267 | 0.79 | PLAA (0.41) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL30389755 | 0.78 | CA12 (0.58) | KDM4EALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9964552-B2 | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-05-08 | — | — | US | claimed |
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2016-10-20 | — | — | US | claimed |
| EP-3063540-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH Technologies Development PTE. Ltd. (SG) | 2016-09-07 | — | — | EP | claimed |
| WO-2015063563-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2015-05-07 | — | — | WO | claimed |
| WO-2023102567-A2 | GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF | DEBOGY MOLECULAR, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-115988962-A | Graftable biocidal linkers and polymers and uses thereof | 德保吉分子公司 | 2023-04-18 | — | — | CN | disclosed |
| US-9964552-B2 | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-05-08 | — | — | US | disclosed |
| US-9964552-B2 | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-05-08 | — | — | US | disclosed |
| US-9964552-B2 | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-05-08 | — | — | US | disclosed |
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2016-10-20 | — | — | US | disclosed |
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2016-10-20 | — | — | US | disclosed |
| EP-3063540-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH Technologies Development PTE. Ltd. (SG) | 2016-09-07 | — | — | EP | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010107866-A2 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107866-A2 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | KDM4E 2077/4885USP2 3473/4885ALDH1A1 412/4885 |
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | AADAT, AASDHPPT, AANAT | KDM4E 1414/4885USP2 4006/4885ALDH1A1 392/4885 |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | KDM4E 2077/4885USP2 3473/4885ALDH1A1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.